biostudies-literatureRiester MRNIA NIH HHSNational Institute of General Medical SciencesNational Institute on AgingNIGMS NIH HHS1691-1700https://www.ebi.ac.uk/biostudies/studies/S-EPMC8522353biostudies-literatureUnknown78(18)<h4>Purpose</h4>Pharmacists are well positioned to provide transitions of care (TOC) services to patients with heart failure (HF); however, hospitalizations for patients with HF likely exceed the capacity of a TOC pharmacist. We developed and validated a tool to help pharmacists efficiently identify high-risk patients with HF and maximize their potential impact by intervening on patients at the highest risk for 30-day all-cause readmission.<h4>Methods</h4>We conducted a retrospective cohort study including adults with HF admitted to a health system between October 1, 2016, and October 31, 2019. We randomly divided the cohort into development (n = 2,114) and validation (n = 1,089) subcohorts. Nine models were applied to select the most important predictors of 30-day readmission. The final tAmerican journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System PharmacistsDevelopment and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF).PMC8522353R01AG065722R21AG061632RF1 AG061221RF1AG061221U54 GM115677U54GM115677Collins CRiester MRZullo ARMcAuliffe LfalseDevelopment and validation of the Tool for Pharmacists to Predict 30-day hospital readmission in patients with Heart Failure (ToPP-HF).<h4>Purpose</h4>Pharmacists are well positioned to provide transitions of care (TOC) services to patients with heart failure (HF); however, hospitalizations for patients with HF likely exceed the capacity of a TOC pharmacist. We developed and validated a tool to help pharmacists efficiently identify high-risk patients with HF and maximize their potential impact by intervening on patients at the highest risk for 30-day all-cause readmission.<h4>Methods</h4>We conducted a retrospective cohort study including adults with HF admitted to a health system between October 1, 2016, and October 31, 2019. We randomly divided the cohort into development (n = 2,114) and validation (n = 1,089) subcohorts. Nine models were applied to select the most important predictors of 30-day readmission. The final t2021-01-01T00:00:00Z2021 Sep2025-04-26T02:39:29.591Z2025-02-18T23:32:21.581ZS-EPMC85223533404852810.1093/ajhp/zxab223